AR126387A1 - Anticuerpos anti-tnfr2 y usos de estos - Google Patents

Anticuerpos anti-tnfr2 y usos de estos

Info

Publication number
AR126387A1
AR126387A1 ARP220101767A ARP220101767A AR126387A1 AR 126387 A1 AR126387 A1 AR 126387A1 AR P220101767 A ARP220101767 A AR P220101767A AR P220101767 A ARP220101767 A AR P220101767A AR 126387 A1 AR126387 A1 AR 126387A1
Authority
AR
Argentina
Prior art keywords
seq
lcvr
hcvr
sequence
chain variable
Prior art date
Application number
ARP220101767A
Other languages
English (en)
Spanish (es)
Inventor
Shuo Wei
Liang Schweizer
Francisco Adrian
Nicola Arturo Aldo Beltraminelli
Pascaline Mary
Matthieu Delince
Qiang Zhang
Jennifer Watkins
Andreas Raue
Original Assignee
Hifibio Hk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hifibio Hk Ltd filed Critical Hifibio Hk Ltd
Publication of AR126387A1 publication Critical patent/AR126387A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP220101767A 2021-07-07 2022-07-06 Anticuerpos anti-tnfr2 y usos de estos AR126387A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163219175P 2021-07-07 2021-07-07

Publications (1)

Publication Number Publication Date
AR126387A1 true AR126387A1 (es) 2023-10-11

Family

ID=84800439

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101767A AR126387A1 (es) 2021-07-07 2022-07-06 Anticuerpos anti-tnfr2 y usos de estos

Country Status (9)

Country Link
EP (1) EP4367140A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024527576A (cg-RX-API-DMAC7.html)
KR (1) KR20240032985A (cg-RX-API-DMAC7.html)
CN (1) CN117980336A (cg-RX-API-DMAC7.html)
AR (1) AR126387A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022308421A1 (cg-RX-API-DMAC7.html)
CA (1) CA3224693A1 (cg-RX-API-DMAC7.html)
TW (1) TW202309096A (cg-RX-API-DMAC7.html)
WO (1) WO2023281313A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL316894A (en) * 2022-05-26 2025-01-01 Pfizer ANTI-TNFR2 ANTIBODIES AND METHODS OF USE THEREOF
WO2024233258A1 (en) * 2023-05-05 2024-11-14 Cureimmune Therapeutics Inc. Anti-tnfr2 antibodies and uses thereof
WO2026119935A1 (en) 2024-12-03 2026-06-11 Resano Gmbh Combination comprising a tumor necrosis factor receptor 2 agonist
WO2026119926A1 (en) 2024-12-03 2026-06-11 Resano Gmbh Agonist polypeptide for use in treating and/or preventing heart failure

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040312A1 (en) * 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
WO2019094559A2 (en) * 2017-11-09 2019-05-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
US20210371537A1 (en) * 2018-09-18 2021-12-02 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
CN113874083A (zh) * 2019-03-01 2021-12-31 梅里麦克制药股份有限公司 抗-tnfr2抗体及其用途
EP3907240A4 (en) * 2019-08-02 2023-02-22 Jiangsu Simcere Pharmaceutical Co., Ltd. ANTI-TNFR2 ANTIBODIES AND USE THEREOF
AU2020348224A1 (en) * 2019-09-17 2022-05-12 Apexigen, Inc. Anti-TNFR2 antibodies and methods of use
CN112480259B (zh) * 2021-02-05 2021-05-04 百奥赛图(北京)医药科技股份有限公司 抗tnfr2抗体及其用途

Also Published As

Publication number Publication date
WO2023281313A1 (en) 2023-01-12
EP4367140A4 (en) 2025-06-18
CN117980336A (zh) 2024-05-03
EP4367140A1 (en) 2024-05-15
KR20240032985A (ko) 2024-03-12
TW202309096A (zh) 2023-03-01
AU2022308421A1 (en) 2024-01-25
JP2024527576A (ja) 2024-07-25
CA3224693A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
PE20231067A1 (es) Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
MY208743A (en) Anti-ms4a4a antibodies and methods of use thereof
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
AR106991A1 (es) Anticuerpos neutralizantes del virus de inmunodeficiencia humana
PE20181089A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
PE20211293A1 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
EA202190235A1 (ru) Антитела к cd33 и способы их применения
AR115192A1 (es) Anticuerpos
MX2022012182A (es) Metodos de uso de anticuerpos anti-trem2.
PH12022551398A1 (en) Anti-mertk antibodies and methods of use thereof
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
AR109683A1 (es) Anticuerpos contra el factor xi y sus usos
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.
AR096601A1 (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
MX2022003074A (es) Anticuerpos anti-cd371, y usos de los mismos.
EP4361177A3 (en) Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
PE20190633A1 (es) Anticuerpos anti-gm-csf y usos de los mismos
MX2022001305A (es) Anticuerpo de dominio proteínico p40 anti-humana y uso del mismo.
AR126971A1 (es) Composiciones y métodos para tratar el síndrome de qt largo
AR128377A1 (es) Anticuerpo contra btla y sus usos
AR125590A1 (es) Anticuerpo cxcr5 antihumano y sus usos